Enliven Therapeutics (ELVN) Depreciation and Depletion (2019 - 2026)
Enliven Therapeutics (ELVN) reported Depreciation and Depletion of $14000.0 for Q1 2026, down 81.08% on a YoY basis from $74000.0 in Q1 2025, and down 69.57% sequentially from $46000.0 in Q4 2025.
Enliven Therapeutics (ELVN) Depreciation and Depletion (2019 - 2026) Analysis & Trends
Enliven Therapeutics (ELVN) has 8 years of Depreciation and Depletion data on file, last reported at $14000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation and Depletion fell 81.08% year-over-year to $14000.0; the trailing twelve-month figure through Mar 2026 stood at $203000.0 (down 34.94% YoY), and the FY2025 full-year result was $263000.0, down 17.03% from the prior year.
- Depreciation and Depletion eased to $14000.0 in Q1 2026, from $46000.0 in the prior quarter.
- In the past five years, Depreciation and Depletion ranged from a high of $400000.0 in Q2 2022 to a low of $14000.0 in Q1 2026.
- A 5-year average of $85529.4 and a median of $74000.0 in 2023 frame the typical range for Depreciation and Depletion.
- Across the five-year window, Depreciation and Depletion jumped 1500.0% in 2022 and slumped 81.5% in 2023, its largest moves.
- Tracing ELVN's Depreciation and Depletion over 5 years: stood at $64000.0 in 2022, then rose by 21.88% to $78000.0 in 2023, then rose by 2.56% to $80000.0 in 2024, then slumped by 42.5% to $46000.0 in 2025, then plunged by 69.57% to $14000.0 in 2026.
- Business Quant data shows ELVN's Depreciation and Depletion at $14000.0 in Q1 2026, $46000.0 in Q4 2025, and $62000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,011.97 Bn | 67,011.68 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.88 Bn | 467.08 Bn | 1.35 Bn | 39.39 Mn |
| 5 | Vertex Pharmaceuticals | 122.20 Bn | 114.96 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.17 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.85 Bn | 50.67 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | - |
| 10 | Enliven Therapeutics | 3.38 Bn | 2.93 Bn | - | 14,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14,000.00 |
| Mar 31, 2026 | 14,000.00 |
| Dec 31, 2025 | 46,000.00 |
| Dec 31, 2025 | 46,000.00 |
| Sep 30, 2025 | 62,000.00 |
| Sep 30, 2025 | 62,000.00 |
| Jun 30, 2025 | 81,000.00 |
| Jun 30, 2025 | 81,000.00 |
| Mar 31, 2025 | 74,000.00 |
| Mar 31, 2025 | 74,000.00 |
| Dec 31, 2024 | 80,000.00 |
| Dec 31, 2024 | 80,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Jun 30, 2024 | 78,000.00 |
| Jun 30, 2024 | 78,000.00 |
| Mar 31, 2024 | 79,000.00 |
| Mar 31, 2024 | 79,000.00 |
| Dec 31, 2023 | 78,000.00 |
| Dec 31, 2023 | 78,000.00 |